menu
    • menu
    [{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"STMC-103H","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Siolta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Siolta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Funding","leadProduct":"STMC-103H","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Siolta Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"7","companyTruncated":"Siolta Therapeutics \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"SymBiosis and Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Series C Financing","leadProduct":"STMC-103H","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Siolta Therapeutics \/ SymBiosis and Khosla Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Siolta Therapeutics \/ SymBiosis and Khosla Ventures"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"STMC-103H","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Siolta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Siolta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Integrium","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2019","type":"Inapplicable","leadProduct":"STMC-103H","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Siolta Therapeutics \/ Integrium","highestDevelopmentStatusID":"6","companyTruncated":"Siolta Therapeutics \/ Integrium"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Series B Financing","leadProduct":"STMC-103H","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Siolta Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Siolta Therapeutics \/ Khosla Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Siolta Therapeutics \/ Khosla Ventures"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Nexilico","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery Platform","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Siolta Therapeutics \/ Siolta Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Siolta Therapeutics \/ Siolta Therapeutics"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Cowellnex","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Siolta Therapeutics \/ Cowellnex","highestDevelopmentStatusID":"2","companyTruncated":"Siolta Therapeutics \/ Cowellnex"}]

    Find Clinical Drug Pipeline Developments & Deals by Siolta Therapeutics

    Menu

    Siolta Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Siolta Therapeutics

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            Siolta Therapeutics

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery

                            Sponsor : Cowellnex

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Siolta Therapeutics and Cowellnex Enter Joint Research Agreement

                            Details : Under the agreement, Siolta will develop live biotherapeutic products with joint research program with Cowellnex for treating necrotizing enterocolitis in infants.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 29, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery

                            Sponsor : Cowellnex

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Siolta Therapeutics

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            Siolta Therapeutics

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery Platform

                            Recipient : Nexilico

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nexilico and Siolta Partner On Microbiome Drug For Necrotizing Enterocolitis

                            Details : The collaboration combines Nexilico's AI-driven discovery platform with Siolta’s expertise in developing targeted biotherapeutics, setting the stage for the treatment approaches in infant health.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 17, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery Platform

                            Recipient : Nexilico

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Siolta Therapeutics

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            Siolta Therapeutics

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : SymBiosis and Khosla Ventures

                            Deal Size : $12.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development

                            Details : The financing aims to support the advancement of the Siolta clinical program STMC-103H, which is being evaluated in Phase I/II clinical trial studies for Atopic Dermatitis and Type 1 Hypersensitivity.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            March 12, 2024

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : SymBiosis and Khosla Ventures

                            Deal Size : $12.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Siolta Therapeutics

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            Siolta Therapeutics

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study Evaluating a Potential First-I...

                            Details : STMC-103H is a Live Biotherapeutic Product (LBP) for the prevention and treatment of atopic diseases (atopic dermatitis, atopic asthma, food allergy, allergic rhinitis) in at-risk newborns based on an immediate family history of atopic diseases.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            July 20, 2022

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Siolta Therapeutics

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            Siolta Therapeutics

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Siolta Therapeutics Awarded NIH Grant

                            Details : The grant will provide funding for the continued development and optimization of manufacturing approaches for live biotherapeutic products containing strictly anaerobic, non-spore forming bacteria as active pharmaceutical ingredients including STMC-103H.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            February 09, 2022

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Siolta Therapeutics

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            Siolta Therapeutics

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allergic Disease Onset Prevention Study

                            Details : STMC-103H is a Microorganism drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            August 12, 2021

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Siolta Therapeutics

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            Siolta Therapeutics

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Khosla Ventures

                            Deal Size : $30.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases

                            Details : The latest round of capital will go towards supporting clinical proof of concept (POC) trials testing the efficacy of their lead LBP product, STMC-103H.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            September 22, 2020

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Khosla Ventures

                            Deal Size : $30.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Siolta Therapeutics

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            Siolta Therapeutics

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Integrium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy

                            Details : STMC-103H is a Microorganism drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypersensitivity, Immediate.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            January 29, 2019

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Integrium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth